A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma

During the last 15 years, tremendous efforts have been made in the medical treatment of metastatic renal cell carcinoma (mRCC). Immune-oncological (IO) combinations are the current standard of care in the first-line setting of mRCC. Here, the current phase 3 trials CM214 (nivolumab/ipilimumab vs. su...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanyi, Philipp, Wiegmann, Jonas Paul, Eggers, Hendrik, Grünwald, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427512/
https://www.ncbi.nlm.nih.gov/pubmed/37434067
http://dx.doi.org/10.1007/s12325-023-02569-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427512/
https://www.ncbi.nlm.nih.gov/pubmed/37434067
http://dx.doi.org/10.1007/s12325-023-02569-z

Ejemplares similares